Loading...
Loading...
PTPI| Name | Value |
|---|---|
| Revenues | 725.4K |
| Cost of Revenue | 264.8K |
| Gross Profit | 460.6K |
| Operating Expense | 9,591.0K |
| Operating I/L | -9,131.0K |
| Other Income/Expense | -143.0K |
| Interest Income | 24.7K |
| Pretax | -9,273.4K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -9,273.4K |
Petros Pharmaceuticals, Inc. specializes in men's health therapeutics, primarily focusing on the commercialization and development of Stendra, a prescription medication for erectile dysfunction (ED). Additionally, the company is involved in the development and commercialization of H100, a patented topical formulation for the treatment of acute Peyronie's disease. Petros Pharmaceuticals also markets a line of ED products in the form of vacuum erection device products, catering to the needs of individuals seeking solutions for men's health issues.
